AgeX Therapeutics

AgeX Therapeutics

Field:

Focus:

Type: Public Corporation
Founded: 2017


AgeX Therapeutics, Inc. is a biotechnology company founded in 2017 by world-leading gerontologist and bioentrepreneur Dr. Michael D. West, Ph.D., who has dedicated his life to the pursuit of understanding nature’s secrets of human aging. He is a highly-regarded pioneer in cellular aging, stem cell research, telomerase and cloning. He previously founded Geron Corporation where under his leadership the cell immortalizing gene known as telomerase was first isolated, he led the collaborative effort that resulted in the first isolation of pluripotent stem cells, and he spearheaded pioneering research to reverse the aging of human cells by nuclear transfer and related reprogramming technologies.

The mission of AgeX is to develop and commercialize novel therapeutics targeting biological aging based on an emerging understanding of the ‘clockwork mechanisms’ of human aging. We plan to apply these technologies in the practice of human medicine to extend human health and life spans.


Leadership
Michael D West
CEO
Past Roles
CEO (BioTime )
CEO (Asterias Biotherapeutics )
CEO (Advanced Cell Technology)


Financial Performance



Funding


Raised Capital
Year
Type
Offered / Sold Amount
Filings
Reported by Press*
Round
2017
Equity
10.0 / 8.9M USD
10M USD
Venture Round
2018
Equity, Other
6.0 / 5.7M USD
5.46M USD
Private Equity
2019
Equity, Convertible Note
5.0 / 4.5M USD
Known Investors
Name
Type
HQ
Other Relevant Investments
Angel
United States
Private Equity
United States
Angel
United Kingdom
Angel
United States
Corporation
United States
Venture Capital
Germany
Corporation
United States
*More data available at: [CB Insights] [CrunchBase] [PitchBook]

Related
News